AUSTRALIAN Firebrick Pharma Limited's Nasodine Nasal Spray is now on sale in Singapore (SIN).
Customers can order the product through Firebrick's newly launched website dedicated to Singapore sales.
Nasodine is classified as a topical antiseptic and does not require approval or licensing by Singapore's Health Sciences Authority (HSA) before sale.
Additionally, Firebrick has received HSA approval for its consumer advertisements for Nasodine as of yesterday.
Nasodine will be the first PVP-I nasal spray available in the region, marking it as a "first-in-class" product.
"We believe that Nasodine will be a valuable product in the wake of the COVID pandemic because of increased awareness and concern about nasal germs," said Firebrick Executive Chairman, Dr Peter Molloy.
In Singapore, Nasodine will be promoted as "the nasal spray that kills germs".
However, in other markets, such as the US, it is marketed solely as a nasal cleanser.
Initially, Nasodine will be sold online, but in the future, it may also be available through pharmacies and other marketing partners, the company stated.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jun 24
